Stock listing

NASDAQ:NRIX Nurix Therapeutics, Inc. Stock

Home listing (NASDAQ) of Nurix Therapeutics, Inc.

Follow Nurix Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:NRIX

$12.85 USD -1.25 (-8.9%)

Close on Nov 20, 2026

Past year -16.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$12.83 – $13.67 USDNov 20, 2026
Volume
2.43M sharesNov 20, 2026
Market cap
$1.40B USDAt the close on Nov 20, 2026 · price × 109.2M shares outstanding
52-week range
$12.83 – $28.23 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$52.17M USDMedian day 1.91M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Nurix Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:NRIX · Home$12.85 USD-1.25 (-8.9%)2,433,363$13.40$13.67$12.83$14.10Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NRIX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$12.85-1.25-8.9%$13.40$13.67$12.832,433,363
$14.10-0.14-1.0%$14.15$14.44$13.652,789,967
$14.24-0.49-3.3%$14.80$14.86$14.112,224,931
$14.73-0.75-4.8%$15.34$15.60$14.682,156,608
$15.48-0.12-0.8%$15.50$15.76$15.191,384,643
$15.60-0.73-4.5%$16.38$16.55$15.551,338,383
$16.33+0.45+2.8%$16.00$16.70$15.922,513,606
$15.88-0.26-1.6%$16.00$16.76$15.753,049,883
$16.14+0.84+5.5%$15.32$16.62$15.275,974,105
$15.30+0.46+3.1%$15.10$15.52$14.792,974,181
$14.84-1.11-7.0%$16.01$16.59$14.807,091,384
$15.95-9.87-38.2%$17.16$17.28$14.7819,559,090
$25.82+0.12+0.5%$25.72$26.55$25.634,386,939
$25.70-1.10-4.1%$26.75$26.96$25.532,348,536
$26.80-0.32-1.2%$26.90$26.92$25.972,311,400
$27.12-0.14-0.5%$27.46$27.99$26.692,375,000
$27.26+0.56+2.1%$26.26$27.28$25.451,957,400
$26.70+1.15+4.5%$25.52$27.05$25.132,563,000
$25.55+0.21+0.8%$25.35$25.82$25.032,336,900
$25.34-0.17-0.7%$25.22$25.49$24.781,910,400
$25.51-0.51-2.0%$25.86$26.23$25.181,933,900
$26.02-0.08-0.3%$26.00$26.31$25.802,928,300
$26.10+1.17+4.7%$24.92$26.34$24.713,979,800
$24.93+0.51+2.1%$24.57$25.29$24.383,064,100
$24.42-0.53-2.1%$24.89$25.36$24.274,318,300
$24.95+1.28+5.4%$23.67$25.14$23.613,753,400
$23.67+1.54+7.0%$22.01$24.01$21.403,820,700
$22.13-0.03-0.1%$22.16$23.24$21.754,680,800
$22.16-0.19-0.9%$22.27$22.58$22.032,850,900
$22.35+0.14+0.6%$22.04$23.23$21.231,525,100
$22.21-0.52-2.3%$22.49$22.60$21.552,344,900
$22.73+0.13+0.6%$22.43$23.10$22.181,631,800
$22.60-0.28-1.2%$23.06$23.06$22.101,154,200
$22.88-0.11-0.5%$22.81$23.31$22.431,006,500
$22.99-0.35-1.5%$23.72$23.75$22.85815,500
$23.34-0.37-1.6%$23.60$23.99$23.211,334,900
$23.71+0.035+0.1%$23.85$23.94$23.342,010,700
$23.68+0.0050.0%$23.57$23.91$23.252,275,400
$23.67+0.66+2.9%$22.86$23.69$22.412,007,900
$23.01-0.64-2.7%$23.78$23.81$22.981,540,100
$23.65-0.23-1.0%$23.76$23.93$23.022,023,100
$23.88-1.79-7.0%$25.49$25.56$23.851,364,000
$25.67+0.26+1.0%$25.32$25.96$25.231,509,600
$25.41-0.03-0.1%$25.73$25.93$25.061,516,700
$25.44-0.06-0.2%$25.32$25.80$25.012,839,500
$25.50+0.35+1.4%$25.79$26.35$25.371,511,900
$25.15+0.32+1.3%$24.87$25.29$24.681,236,400
$24.83-0.69-2.7%$25.47$25.50$24.271,251,000
$25.52+0.42+1.7%$25.01$26.14$24.951,330,800
$25.10-0.71-2.8%$26.31$26.65$25.001,321,700
$25.81-0.45-1.7%$25.89$25.99$25.501,029,500
$26.26+0.13+0.5%$26.46$26.70$25.911,027,400
$26.13-0.010.0%$25.42$26.42$25.361,287,900
$26.14+0.82+3.2%$25.19$26.22$24.971,232,100
$25.32-0.50-1.9%$25.82$26.16$24.951,381,500
$25.82-0.22-0.8%$26.35$26.92$25.391,736,100
$26.04+0.26+1.0%$25.47$26.11$25.471,597,400
$25.78-0.43-1.6%$26.00$26.23$25.171,244,200
$26.21-0.665-2.5%$26.52$26.87$26.13929,200
$26.88+0.165+0.6%$26.80$27.50$26.241,256,800
$26.71-0.24-0.9%$26.77$27.23$26.44551,900
$26.95+0.68+2.6%$26.72$27.38$26.381,176,300
$26.27-0.45-1.7%$26.37$26.69$25.86874,200
$26.72-0.33-1.2%$27.41$27.50$26.701,485,900
$27.05-0.74-2.7%$27.33$27.57$26.681,086,900
Ticker
NASDAQ:NRIX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Nurix Therapeutics, Inc. news

Nurix Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
29 in the last 12 months · 182 in all · newest Nov 11, 2026 · oldest 2020
Decks
35 decks · latest Oct 29, 2026

Where Nurix Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:NRIX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:NRIXBOATSUnited StatesUSD

Valuation

EV/sales 1.0× against a median of 19.0×: 2nd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Aug 31, 2026 · price Nov 20, 2026

Enterprise value
$683.6M USD
P/E
4.8×
EV/sales
1.0×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
1.4×
Gross margin
Not reported
Operating margin
41.3%
Net margin
42.0%
Debt to equity
0.0×
Beta vs S&P 500
1.15

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Nurix Therapeutics, Inc. · NASDAQ:NRIXUS$1.40BUS$683.6M4.8×1.0×n/a1.4×42.0%0.0×1.15
Damora Therapeutics, Inc. · NASDAQ:DMRAUS$1.44BUS$910.0Mn/an/an/a2.9×n/a0.0×0.88
Vir Biotechnology, Inc. · NASDAQ:VIRUS$1.44BUS$1.07Bn/a3.5×n/a1.6×−61.0%0.1×1.82
LigaChem Biosciences Inc. · KRX:141080US$1.43BUS$1.15Bn/a15.5×n/a4.8×−180.9%0.0×n/a
Kailera Therapeutics, Inc. · NASDAQ:KLRAUS$1.43BUS$539.5Mn/an/an/a1.4×n/a0.0×1.28
Sarepta Therapeutics, Inc. · NASDAQ:SRPTUS$1.43BUS$1.41Bn/a0.7×n/a0.9×−5.9%0.6×1.70
ADARx Pharmaceuticals, Inc. · NASDAQ:ADRXUS$1.42BUS$521.8Mn/a77.6×n/a2.5×n/a0.0×n/a
Intellia Therapeutics, Inc. · NASDAQ:NTLAUS$1.40BUS$1.00Bn/a19.0×n/a2.3×−805.7%0.1×2.01
Tyra Biosciences, Inc. · NASDAQ:TYRAUS$1.39BUS$694.9Mn/an/an/a2.0×n/a0.0×0.40
Wuhan Healthgen Biotechnology Corp Class A · SSE:688765US$1.37BUS$1.37Bn/a164×n/a3.3×−252.8%0.1×n/a
Rapport Therapeutics, Inc. · NASDAQ:RAPPUS$1.37BUS$987.3Mn/a49.4×n/a3.5×−752.4%0.0×1.16
Median of the othersUS$1.42BUS$995.2M19.0×2.4×−216.9%0.0×1.28

Forecasts

8 strong buy · 5 buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
33.50 USD · Analysts' mean
EPS, year to Nov 2026
3.02 · 3 analysts
Revenue, year to Nov 2026
744.8M · 4 analysts

Team and board

Officers

OfficerRole
Arthur T. SandsPresident, Chief Executive Officer, and Board Director
Arati V. RaoChief Medical Officer

Board

DirectorRole
Julia P. GregoryChair

Events

QuarterResultsShare move
Q3 2026Oct 12, 2026−1.0%
Q2 2026Jul 9, 2026 · After close−6.6%
Q1 2026Apr 14, 2026+6.7%
Q4 2025Jan 28, 2026 · After close−1.6%
Q3 2025Oct 9, 2025 · After close−10.1%
Q2 2025Jul 9, 2025 · After close−3.9%
Q1 2025Apr 8, 2025 · After close+3.7%
Q4 2024Feb 13, 2025 · Before open+1.5%
Q3 2024Oct 11, 2024 · After close+6.5%
Q2 2024Jul 11, 2024 · After close+8.1%
All 20 quarters
QuarterResultsShare move
Q1 2024Apr 10, 2024 · Before open−10.2%
Q4 2023Feb 15, 2024 · After close+0.2%
Q3 2023Oct 12, 2023 · After close+2.3%
Q2 2023Jul 13, 2023 · After close−3.2%
Q1 2023Apr 13, 2023 · After close+20.6%
Q4 2022Feb 9, 2023 · After close+3.7%
Q3 2022Oct 6, 2022 · After close−7.2%
Q2 2022Jul 7, 2022 · After close+14.5%
Q1 2022Apr 8, 2022 · After close−16.5%
Q4 2021Jan 27, 2022 · After close+2.1%

Open Events

Decks

DeckKindSlidesDate
9th Annual TPD & Induced Proximity Summit (October 2026)Conference35 slidesOct 29, 2026
EHA 2026 Annual MeetingConference15 slidesJun 14, 2026
Merger or Acquisition (June 2026)Merger or acquisition19 slidesJun 8, 2026
Technical Presentation (April 2026)Technical21 slidesApril 2026
J.P. Morgan Healthcare Conference 2026Conference27 slidesJan 12, 2026
ASH 2025 (American Society of Hematology annual meeting)Conference47 slidesDec 9, 2025
Investor Presentation (October 2025)Investor deck53 slidesOct 22, 2025
Investor Presentation (September 2025)Investor deck12 slidesSep 3, 2025
EHA 2025 Investor EventConference35 slidesJun 12, 2025
Investor Presentation (January 2025)Investor deck31 slidesJan 13, 2025
All 35 decks
DeckKindSlidesDate
American Society of Hematology Investor Event 2024Conference44 slidesDec 10, 2024
7th Annual TPD & Induced Proximity Summit 2024Conference20 slidesOct 30, 2024
12th International Workshop on Waldenstrom's Macroglobulinemia 2024Conference17 slidesOct 19, 2024
Investor Presentation (September 2024)Investor deck37 slidesSep 5, 2024
Discovery on Target 2024Conference19 slidesSeptember 2024
Technical Presentation (June 2024)Technical32 slidesJun 17, 2024
EHA Hybrid Congress 2024Conference16 slidesJun 16, 2024
Investor Presentation (January 2024)Investor deck44 slidesJan 8, 2024
ASH Event Presentation 2023Conference43 slidesDec 11, 2023
Investor Presentation (November 2023)Investor deck40 slidesNov 13, 2023
6th Annual Targeted Protein Degradation Summit (October 2023)Conference31 slidesOct 31, 2023
Protein Degradation & Targeting Undruggables Congress Europe 2023Conference41 slidesSep 19, 2023
3rd Annual Ligase Targeting Drug Development (April 2023)Conference28 slidesApr 12, 2023
Dana Farber TPD Webinar (February 2023)Conference28 slidesFeb 2, 2023
Investor Presentation (January 2023)Investor deck35 slidesJan 9, 2023
ASH Event Presentation 2022Conference52 slidesDec 12, 2022
TPD Assay Summit 2022Conference30 slidesDec 8, 2022
5th Annual TPD Summit (October 2022)Conference25 slidesOct 26, 2022
ACS Fall Meeting 2022Conference28 slidesAug 23, 2022
Investor Day (May 2022)Investor day147 slidesMay 26, 2022
17th Annual Drug Discovery Chemistry 2022Conference31 slidesApr 19, 2022
Investor Presentation (January 2022)Investor deck30 slidesJan 10, 2022
4th Annual Targeted Protein Degradation (TPD) Summit 2021Conference24 slidesOct 27, 2021
Technical Presentation (December 2020)Technical10 slidesDec 7, 2020
TPD Conference 2020Conference20 slidesOct 14, 2020

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$250M raised · US$10.21 a share · J.P. Morgan Securities LLC +4
Dealers: J.P. Morgan Securities LLC (co-lead), Jefferies LLC (co-lead), Stifel, Nicolaus & Company, Incorporated (co-lead), Oppenheimer & Co. Inc., Robert W. Baird & Co. Incorporated
Buyers: General Atlantic; Redmile Group; Braidwell LP; Deep Track Capital; Perceptive Advisors; Trails Edge Capital Partners; Vestal Point Capital
Use of proceeds: Clinical development of drug candidates incl. bexobrutideg in CLL and autoimmune indications, R&D to expand pipeline, working capital and general purposes
Oct 27, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$19.00 a share on Jul 23, 2020.

Price
US$19.00 a share
Shares offered
11,000,000 shares of common stock
Offering size
US$209 million
Underwriters' option
Up to 1,650,000 more shares
Underwriters
J.P. Morgan, Piper Sandler, Stifel, Needham & Company · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceMay 5, 2020
Filed publiclyJul 2, 2020
Amended twiceNewest Jul 23, 2020
Shares registered with an exchangeJul 20, 2020
Declared effective by the SECJul 23, 2020
Final prospectus, with the priceJul 24, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Jul 24, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue84.0M54.5M77.0M38.6M29.8M17.8M31.1M
Research and development316.9M221.6M189.1M184.5M116.4M66.5M45.0M
Operating income-285.7M-213.0M-155.1M-183.9M-117.9M-65.0M-22.2M
Depreciation and amortization8.74M9.32M7.53M5.35M2.79M2.18M2.35M
EBITDA-276.9M-203.7M-147.5M-178.5M-115.1M-62.8M-19.9M
Income before tax-263.7M-193.3M-143.9M-180.4M-117.1M-63.8M-21.5M
Income tax760.0K270.0K00131.0K-20.5M239.0K
Net income-264.5M-193.6M-143.9M-180.4M-117.2M-43.2M-21.7M
Earnings per share, basic-3.05-2.88-2.65-3.71-2.73-2.76-6.59
Earnings per share, diluted-3.05-2.88-2.65-3.71-2.73-2.76-6.59

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents247.0M110.0M54.6M64.5M80.5M119.4M34.8M
Short-term investments244.7M215.2M161.8M2.90M
Receivables0006.00M
Current assets606.8M619.4M295.5M318.4M311.1M298.4M39.4M
Property, plant and equipment22.5M17.8M16.8M17.2M11.3M6.67M3.87M
Total assets688.1M669.3M355.6M416.8M476.8M396.3M44.0M
Accounts payable11.2M11.5M6.40M5.06M6.65M3.41M1.60M
Current liabilities86.5M95.9M87.0M70.7M66.3M44.5M16.1M
Total liabilities149.4M142.3M155.1M113.1M134.5M106.1M53.6M
Shareholders' equity538.7M527.0M200.5M303.7M342.3M290.3M-57.7M
Shares outstanding101.8M75.9M48.7M47.2M44.7M38.9M3.60M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-249.5M-172.6M-81.4M-159.8M-84.4M-80.0K601.0K
Capital spending-14.0M-9.27M-8.40M-12.2M-5.66M-4.55M-1.65M
Free cash flow-263.5M-181.9M-89.8M-172.1M-90.0M-4.63M-1.05M
Cash from investing147.9M-257.7M68.3M27.2M-108.3M-254.4M8.50M
Cash from financing238.6M485.7M3.22M117.2M153.9M339.0M126.0K
Change in cash137.0M55.4M-9.85M-15.4M-38.7M84.5M9.22M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2026Big-stake noticeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
4 · Change in ownershipNov 4, 2026Insider tradeSEC
144 · Notice of proposed saleNov 4, 2026Other filingsSEC
144 · Notice of proposed saleNov 3, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportNov 3, 2026Current reportSEC
4 · Change in ownershipNov 2, 2026Insider tradeSEC
4 · Change in ownershipNov 2, 2026Insider tradeSEC
4 · Change in ownershipNov 2, 2026Insider tradeSEC
144 · Notice of proposed saleNov 2, 2026Other filingsSEC
4 · Change in ownershipOct 15, 2026Insider tradeSEC
144 · Notice of proposed saleOct 14, 2026Other filingsSEC
4 · Change in ownershipOct 14, 2026Insider tradeSEC
10-Q · Quarterly reportOct 13, 2026Quarterly reportSEC
8-K · Current reportOct 13, 2026ResultsSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
144 · Notice of proposed saleOct 2, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeSep 23, 2026Big-stake noticeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
144 · Notice of proposed saleSep 2, 2026Other filingsSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
144 · Notice of proposed saleAug 5, 2026Other filingsSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipAug 4, 2026Insider tradeSEC
144 · Notice of proposed saleAug 4, 2026Other filingsSEC
144 · Notice of proposed saleAug 4, 2026Other filingsSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
144 · Notice of proposed saleAug 3, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeJul 31, 2026Big-stake noticeSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
4 · Change in ownershipJul 30, 2026Insider tradeSEC
10-Q · Quarterly reportJul 9, 2026Quarterly reportSEC
8-K · Current reportJul 9, 2026ResultsSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
144 · Notice of proposed saleJul 2, 2026Other filingsSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
4 · Change in ownershipJun 25, 2026Insider tradeSEC
144 · Notice of proposed saleJun 25, 2026Other filingsSEC
144 · Notice of proposed saleJun 25, 2026Other filingsSEC
8-K · Current reportJun 11, 2026Current reportSEC
8-K · Current reportJun 8, 2026Material contractSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
144 · Notice of proposed saleJun 2, 2026Other filingsSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
8-K · Current reportMay 15, 2026Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 6, 2026Big-stake noticeSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
144 · Notice of proposed saleMay 5, 2026Other filingsSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
144 · Notice of proposed saleMay 4, 2026Other filingsSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
4 · Change in ownershipApr 30, 2026Insider tradeSEC
4 · Change in ownershipApr 30, 2026Insider tradeSEC
4 · Change in ownershipApr 30, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 24, 2026Big-stake noticeSEC
10-Q · Quarterly reportApr 8, 2026Quarterly reportSEC
8-K · Current reportApr 8, 2026ResultsSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
144 · Notice of proposed saleApr 2, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersMar 27, 2026Annual reportSEC
DEFA14A · Additional proxy materialMar 27, 2026Meeting noticeSEC
DEF 14A · Proxy statementMar 27, 2026Meeting noticeSEC
8-K · Current reportMar 6, 2026Current reportSEC
424B5 · ProspectusMar 6, 2026Offer documentSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 10, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 9, 2026Other filingsSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
S-8 · Registration statement for employee plansJan 28, 2026Offer documentSEC
10-K · Annual reportJan 28, 2026Annual reportSEC
8-K · Current reportJan 28, 2026ResultsSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
8-K · Current reportJan 12, 2026Current reportSEC
4 · Change in ownershipDec 18, 2025Insider tradeSEC
144 · Notice of proposed saleDec 18, 2025Other filingsSEC
8-K · Current reportDec 9, 2025Current reportSEC
4 · Change in ownershipNov 24, 2025Insider tradeSEC
144 · Notice of proposed saleNov 24, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
4 · Change in ownershipNov 10, 2025Insider tradeSEC
3 · Initial statement of ownershipNov 10, 2025Insider tradeSEC
8-K · Current reportNov 10, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2025Big-stake noticeSEC
4 · Change in ownershipNov 3, 2025Insider tradeSEC
144 · Notice of proposed saleNov 3, 2025Other filingsSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
4 · Change in ownershipOct 23, 2025Insider tradeSEC
424B5 · ProspectusOct 22, 2025Offer documentSEC
8-K · Current reportOct 22, 2025Current reportSEC
FWP · Free writing prospectusOct 22, 2025Offer documentSEC
8-K · Current reportOct 22, 2025Current reportSEC
10-Q · Quarterly reportOct 9, 2025Quarterly reportSEC
8-K · Current reportOct 9, 2025ResultsSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
8-K · Current reportSep 3, 2025Current reportSEC
8-K · Current reportAug 22, 2025Management or board changeSEC
4 · Change in ownershipAug 1, 2025Insider tradeSEC
144 · Notice of proposed saleAug 1, 2025Other filingsSEC
4 · Change in ownershipJul 30, 2025Insider tradeSEC
4 · Change in ownershipJul 30, 2025Insider tradeSEC
4 · Change in ownershipJul 30, 2025Insider tradeSEC
10-Q · Quarterly reportJul 9, 2025Quarterly reportSEC
8-K · Current reportJul 9, 2025ResultsSEC
8-K · Current reportJun 12, 2025Current reportSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
4 · Change in ownershipMay 19, 2025Insider tradeSEC
8-K · Current reportMay 19, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
144 · Notice of proposed saleMay 2, 2025Other filingsSEC
4 · Change in ownershipApr 30, 2025Insider tradeSEC
4 · Change in ownershipApr 30, 2025Insider tradeSEC
4 · Change in ownershipApr 30, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 23, 2025Big-stake noticeSEC
10-Q · Quarterly reportApr 8, 2025Quarterly reportSEC
8-K · Current reportApr 8, 2025ResultsSEC
DEFA14A · Additional proxy materialMar 28, 2025Meeting noticeSEC
ARS · Annual report to shareholdersMar 28, 2025Annual reportSEC
DEF 14A · Proxy statementMar 28, 2025Meeting noticeSEC
UPLOAD · Letter from the SECMar 19, 2025Other filingsSEC
CORRESP · Letter to the SECMar 13, 2025Other filingsSEC
4 · Change in ownershipMar 13, 2025Insider tradeSEC
3 · Initial statement of ownershipMar 13, 2025Insider tradeSEC
8-K · Current reportMar 13, 2025Management or board changeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
144 · Notice of proposed saleMar 3, 2025Other filingsSEC
UPLOAD · Letter from the SECFeb 28, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
4 · Change in ownershipFeb 3, 2025Insider tradeSEC
144 · Notice of proposed saleJan 31, 2025Other filingsSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
S-8 · Registration statement for employee plansJan 28, 2025Offer documentSEC
10-K · Annual reportJan 28, 2025Annual reportSEC
8-K · Current reportJan 28, 2025ResultsSEC
8-K · Current reportJan 13, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 10, 2025Big-stake noticeSEC
4 · Change in ownershipJan 2, 2025Insider tradeSEC
144 · Notice of proposed saleJan 2, 2025Other filingsSEC
8-K · Current reportDec 10, 2024Current reportSEC
SCHEDULE 13G · Big-stake noticeDec 6, 2024Big-stake noticeSEC
4 · Change in ownershipDec 2, 2024Insider tradeSEC
144 · Notice of proposed saleDec 2, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 7, 2024Big-stake noticeSEC
4 · Change in ownershipNov 4, 2024Insider tradeSEC

This page holds 200 of 567 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Nurix Therapeutics, Inc.’s releases · as of Sep 30, 2026

Common shares
109,249,814
Fully diluted
109,249,814

Fully diluted

LineSharesAs of
Common shares109,249,814Sep 30, 2026

Share count over time

CountShares
Sep 30, 2026109,249,814

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
BlackRock8.8MUS$209MSep 30, 2026
Redmile Group, LLC7.9MUS$187MSep 30, 2026
Vestal Point Capital, LP7.03MUS$167MSep 30, 2026
Vanguard6.56MUS$155MSep 30, 2026
Deep Track Capital, LP6MUS$142MSep 30, 2026
Perceptive Advisors LLC5.37MUS$127MSep 30, 2026
Morgan Stanley5.25MUS$124MSep 30, 2026
Rubric Capital Management LP4.97MUS$118MSep 30, 2026
Fidelity4.68MUS$111MSep 30, 2026
Baker Bros. Advisors LP4.66MUS$110MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
T. Rowe Price4.57MUS$108MSep 30, 2026
State Street4.43MUS$105MSep 30, 2026
General Atlantic, L.P.3.03MUS$71.9MSep 30, 2026
Geode Capital2.52MUS$59.7MSep 30, 2026
ARK1.85MUS$43.9MSep 30, 2026
Capital Group1.79MUS$42.4MSep 30, 2026
Trails Edge Capital Partners, LP1.57MUS$37.3MSep 30, 2026
Dimensional1.31MUS$31.2MSep 30, 2026
Eventide Asset Management, LLC1.3MUS$30.8MSep 30, 2026
Goldman Sachs1.28MUS$30.4MSep 30, 2026
Arrowstreet Capital, Limited Partnership1.28MUS$30.4MSep 30, 2026
Bank of America1.25MUS$29.6MSep 30, 2026
Kynam Capital Management, LP1.19MUS$28.3MSep 30, 2026
Pictet Asset Management Holding SA1.13MUS$26.8MSep 30, 2026
Woodline Partners LP1.06MUS$25.2MSep 30, 2026
BNP Paribas1.05MUS$24.8MSep 30, 2026
Affinity Asset Advisors, LLC968KUS$22.9MSep 30, 2026
Soleus Capital Management, L.P.892KUS$21.2MSep 30, 2026
Northern Trust877KUS$20.8MSep 30, 2026
Marshall Wace, LLP873KUS$20.7MSep 30, 2026
Braidwell LP871KUS$20.7MSep 30, 2026
Nuveen866KUS$20.5MSep 30, 2026
Amova Asset Management Americas, Inc.863KUS$20.4MSep 30, 2026
Sumitomo Mitsui Trust Group, Inc.863KUS$20.5MSep 30, 2026
Schwab862KUS$20.4MSep 30, 2026
UBS832KUS$19.7MSep 30, 2026
ADAR1 Capital Management, LLC813KUS$19.3MSep 30, 2026
Wellington789KUS$18.7MSep 30, 2026
Kennedy Capital Management LLC753KUS$17.9MSep 30, 2026
Handelsbanken Fonder AB750KUS$17.8MSep 30, 2026
Lord, Abbett & Co. LLC729KUS$17.3MSep 30, 2026
Raymond James Financial Inc635KUS$15.1MSep 30, 2026
Sofinnova Investments, Inc.524KUS$12.4MSep 30, 2026
Russell Investments Group, Ltd.504KUS$11.9MSep 30, 2026
Elmind Capital, LP460KUS$10.9MSep 30, 2026
Foresite Capital Management V, LLC459KUS$10.9MSep 30, 2026
Qube Research & Technologies Ltd449KUS$10.6MSep 30, 2026
Rhenman & Partners Asset Management AB440KUS$10.4MSep 30, 2026
Millennium413KUS$9.79MSep 30, 2026
Citigroup Inc391KUS$9.28MSep 30, 2026

This page holds 50 of 226 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Total Stock Market Index Fund3.27MUS$79.4MJun 30, 2026
iShares Russell 2000 ETF2.51MUS$60.8MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF2.46MUS$59.7MJun 30, 2026
SMALLCAP World Fund Inc1.74MUS$42.2MJun 30, 2026
ARK Genomic Revolution ETF1.68MUS$39MJul 31, 2026
Eventide Healthcare & Life Sciences Fund1.3MUS$31.5MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.1.19MUS$28.8MJun 30, 2026
Vanguard Extended Market Index Fund1.11MUS$27MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.1.1MUS$26.6MJun 30, 2026
Fidelity Small Cap Index Fund1.05MUS$24.3MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
Fidelity Small Cap Growth Fund948KUS$22MJul 31, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund943KUS$22.9MJun 30, 2026
iShares Biotechnology ETF695KUS$16.9MJun 30, 2026
iShares Russell 2000 Growth ETF682KUS$16.5MJun 30, 2026
Fidelity Growth Company Fund646KUS$11.5MMay 31, 2026
Vanguard Explorer Fund530KUS$12.3MJul 31, 2026
Vanguard Russell 2000 Index Fund522KUS$9.28MMay 31, 2026
Fidelity Extended Market Index Fund501KUS$8.89MMay 31, 2026
Fidelity Small Cap Growth K6 Fund476KUS$11MJul 31, 2026
Schwab U.S. Small-Cap ETF466KUS$8.28MMay 31, 2026
Select Biotechnology Portfolio333KUS$5.92MMay 31, 2026
iShares Micro-Cap ETF321KUS$7.79MJun 30, 2026
Nuveen Quant Small/Mid Cap Equity Fund315KUS$7.31MJul 31, 2026
Dimensional U.S. Small Cap ETF313KUS$7.27MJul 31, 2026
U.S. Micro Cap Portfolio310KUS$7.2MJul 31, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund285KUS$5.05MMay 31, 2026
U.S. Small Cap Portfolio271KUS$6.29MJul 31, 2026
Vanguard Strategic Small-Cap Equity Fund266KUS$6.44MJun 30, 2026
College Retirement Equities Fund - Total Global Stock Account255KUS$6.19MJun 30, 2026
Schwab Small-Cap Index Fund233KUS$5.4MJul 31, 2026
Vanguard Health Care Index Fund229KUS$4.07MMay 31, 2026
Fidelity Series Small Cap Core Fund217KUS$5.04MJul 31, 2026
First Trust Small Cap Growth AlphaDEX Fund213KUS$4.94MJul 31, 2026
iShares Russell 2000 Value ETF206KUS$4.99MJun 30, 2026
Fidelity Small Cap Discovery Fund200KUS$4.64MJul 31, 2026
Fidelity Total Market Index Fund182KUS$3.24MMay 31, 2026
Dimensional U.S. Core Equity 2 ETF181KUS$4.21MJul 31, 2026
Master Small Cap Index Series179KUS$4.35MJun 30, 2026
Fidelity Series Small Cap Discovery Fund175KUS$4.05MJul 31, 2026
Fidelity Growth Company K6 Fund162KUS$2.87MMay 31, 2026
Fidelity Series Total Market Index Fund147KUS$2.62MMay 31, 2026
Fidelity Enhanced Small Cap Core ETF145KUS$3.53MJun 30, 2026
Carillon Eagle Small Cap Growth Fund142KUS$3.44MJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF135KUS$3.28MJun 30, 2026
Nuveen Small Cap Blend Index Fund127KUS$2.95MJul 31, 2026
Fidelity Series Growth Company Fund118KUS$2.09MMay 31, 2026
Invesco RAFI US 1500 Small-Mid ETF114KUS$2.65MJul 31, 2026
BlackRock Advantage Small Cap Core Fund113KUS$2MMay 29, 2026
T. Rowe Price Integrated U.S. Small-Mid Cap Core Equity Fund107KUS$2.59MJun 30, 2026
T.Rowe Price Small Cap Growth Portfolio105KUS$2.56MJun 30, 2026

This page holds 50 of 203 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
van Houte Hans
Officer: Chief Financial Officer
Sale3,300USD 15.38US$50,762Nov 4, 2026
van Houte Hans
Officer: Chief Financial Officer
Sale1,469USD 16.20US$23,800Nov 4, 2026
Ring Christine
Officer: Chief Legal Officer
Sale6,113USD 25.83US$158KNov 3, 2026
Ring Christine
Officer: Chief Legal Officer
Sale9,527USD 25.74US$245KNov 2, 2026
Ring Christine
Officer: Chief Legal Officer
Sale1,075USD 26.76US$28,770Nov 2, 2026
Hansen Gwenn
Officer: Chief Scientific Officer
Sale1,452USD 26.80US$38,914Nov 2, 2026
Hansen Gwenn
Officer: Chief Scientific Officer
Sale3,957USD 26.28US$104KOct 30, 2026
Ring Christine
Officer: Chief Legal Officer
Sale3,957USD 26.28US$104KOct 30, 2026
van Houte Hans
Officer: Chief Financial Officer
Sale2,834USD 26.28US$74,475Oct 30, 2026
Hansen Gwenn
Officer: Chief Scientific Officer
Sale1,452USD 25.00US$36,300Oct 15, 2026
All 36 trades
TradeTradeSharesPriceValueDate
Gregory Julia P
Director
Sale22,583USD 23.40US$529KOct 14, 2026
Ring Christine
Officer: Chief Legal Officer
Sale5,786USD 23.19US$134KOct 2, 2026
Ring Christine
Officer: Chief Legal Officer
Sale5,387USD 25.69US$138KSep 2, 2026
Ring Christine
Officer: Chief Legal Officer
Sale400USD 26.64US$10,656Sep 2, 2026
Hansen Gwenn
Officer: Chief Scientific Officer
Sale1,452USD 25.47US$36,982Sep 1, 2026
Hansen Gwenn
Officer: Chief Scientific Officer
Sale4,356USD 25.00US$109KAug 5, 2026
Hansen Gwenn
Officer: Chief Scientific Officer
Sale1,500USD 23.87US$35,805Aug 4, 2026
Hansen Gwenn
Officer: Chief Scientific Officer
Sale2,611USD 24.64US$64,335Aug 4, 2026
van Houte Hans
Officer: Chief Financial Officer
Sale1,794USD 23.89US$42,859Aug 4, 2026
van Houte Hans
Officer: Chief Financial Officer
Sale2,967USD 24.65US$73,137Aug 4, 2026
Ring Christine
Officer: Chief Legal Officer
Sale16,589USD 23.05US$382KAug 3, 2026
Hansen Gwenn
Officer: Chief Scientific Officer
Sale3,847USD 23.38US$89,943Jul 30, 2026
Ring Christine
Officer: Chief Legal Officer
Sale3,847USD 23.38US$89,943Jul 30, 2026
van Houte Hans
Officer: Chief Financial Officer
Sale2,845USD 23.38US$66,516Jul 30, 2026
Ring Christine
Officer: Chief Legal Officer
Sale11,008USD 23.56US$259KJul 2, 2026
Hansen Gwenn
Officer: Chief Scientific Officer
Sale5,394USD 20.00US$108KJun 25, 2026
Ring Christine
Officer: Chief Legal Officer
Sale28,935USD 20.06US$580KJun 25, 2026
Ring Christine
Officer: Chief Legal Officer
Sale8,148USD 16.60US$135KJun 2, 2026
van Houte Hans
Officer: Chief Financial Officer
Sale13,473USD 16.58US$223KMay 5, 2026
van Houte Hans
Officer: Chief Financial Officer
Sale582USD 17.18US$9,999May 5, 2026
Ring Christine
Officer: Chief Legal Officer
Sale8,148USD 16.96US$138KMay 4, 2026
Ring Christine
Officer: Chief Legal Officer
Sale5,394USD 16.76US$90,403May 1, 2026
Hansen Gwenn
Officer: Chief Scientific Officer
Sale3,214USD 16.65US$53,513Apr 30, 2026
Ring Christine
Officer: Chief Legal Officer
Sale3,214USD 16.65US$53,513Apr 30, 2026
van Houte Hans
Officer: Chief Financial Officer
Sale2,388USD 16.65US$39,760Apr 30, 2026
Ring Christine
Officer: Chief Legal Officer
Sale8,148USD 15.24US$124KApr 2, 2026

Big stakes

StakeStakeSharesDateFiling
BlackRock, Inc.8.20%6.28MMar 31, 2025Schedule 13G
Baker Bros. Advisors LP7.20%7.53MDec 31, 2025Schedule 13G
Vestal Point Capital, LP6.40%7.03MSep 30, 2026Schedule 13G
Deep Track Capital, LP5.49%6MSep 30, 2026Schedule 13G
Vanguard Capital Management LLC5.03%5.2MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Lori Kunkel
Other companies: Enliven Therapeutics, Inc. (Director · Since at least Apr 8, 2024); ORIC Pharmaceuticals, Inc. (Director · Since at least Jun 9, 2020); Tocagen Inc (Director · Jun 21, 2018 – Oct 4, 2019 · Past); Curis, Inc. (Director · Jan 22, 2018 – Jan 31, 2022 · Past); Loxo Oncology Inc (Director · Nov 2, 2017 – Feb 15, 2019 · Past)
Director · Jul 23, 2020 – May 19, 2025 · Past
David Lacey
Other companies: Arcus Biosciences, Inc. (Director · Since at least May 21, 2020); Atreca Inc (Director · Jun 19, 2019 – Jun 13, 2023 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 18, 2020 · Past)
Director · Since at least Jul 23, 2020
Leon Chen
Other companies: Eikon Therapeutics, Inc. (Director · Since at least Feb 4, 2026); LogicBio Therapeutics Inc (Director · Oct 18, 2018 – Nov 16, 2022 · Past)
Director · Jul 23, 2020 – May 6, 2021 · Past
Arthur T. Sands
Other companies: Lexicon Pharmaceuticals, Inc. (President & CEO, Director · Feb 23, 2011 – Feb 28, 2014 · Past)
President, Chief Executive Officer, and Board Director · Since at least Jul 23, 2020
Paul M Silva
Other companies: Rapport Therapeutics, Inc. (Director · Since at least Jun 17, 2025)
Director · Since at least May 19, 2025
Arati V. RaoChief Medical Officer · Since at least Nov 11, 2026
Christine RingChief Legal Officer · Since at least Apr 30, 2025
Edward C SaltzmanDirector · Since at least May 20, 2024
Gwenn M. HansenChief Scientific Officer · Oct 5, 2026 – Nov 12, 2026 · Past
Hans van HouteChief Financial Officer · Since at least Jul 23, 2020
All 16 people
PersonSeat
Jason KantorChief Business Officer · May 15, 2025 – Nov 12, 2026 · Past
John NorthcottChief Commercial Officer · Jan 12, 2026 – Nov 12, 2026 · Past
Julia P. GregoryChair · Since at least Oct 14, 2026
Pasit PhiasivongsaChief Technical Officer · Jan 13, 2025 – Nov 12, 2026 · Past
Roger DanseyDirector · Nov 10, 2025 – Nov 11, 2026 · Past
Wes BurwellChief Human Resources Officer · Aug 20, 2026 – Nov 12, 2026 · Past

Open People

Log in to ask 6ix AI your own questions about Nurix Therapeutics, Inc.